Who makes Reyanning mixture?

Reyanning mixture is developed by China Academy of Chinese Medical Sciences.

What development phase is Reyanning mixture in?

Reyanning mixture is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Reyanning mixture

China Academy of Chinese Medical Sciences · FDA-approved active Small molecule Quality 0/100

Reyanning mixture, developed by the China Academy of Chinese Medical Sciences, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Reyanning mixture
Also known as	Reyanning
Sponsor	China Academy of Chinese Medical Sciences
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Registration of the Study of Reyanning Mixture (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Reyanning mixture CI brief — competitive landscape report
Reyanning mixture updates RSS · CI watch RSS
China Academy of Chinese Medical Sciences portfolio CI